These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19726995)

  • 1. Disease-modifying treatment in systemic sclerosis: current status.
    Quillinan NP; Denton CP
    Curr Opin Rheumatol; 2009 Nov; 21(6):636-41. PubMed ID: 19726995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):192-5. PubMed ID: 18942346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous lupus erythematosus: update of therapeutic options part II.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e195-213. PubMed ID: 20800319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating immunobullous diseases: an update.
    Reynaert S; Black MM
    Dermatol Nurs; 2004 Feb; 16(1):29-34, 70. PubMed ID: 15022502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.
    Cocito D; Grimaldi S; Paolasso I; Falcone Y; Antonini G; Benedetti L; Briani C; Fazio R; Jann S; Matà S; Sabatelli M; Nobile-Orazio E;
    Eur J Neurol; 2011 Dec; 18(12):1417-21. PubMed ID: 21819489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the therapy of Wegener's granulomatosis.
    Hellmich B; Lamprecht P; Gross WL
    Curr Opin Rheumatol; 2006 Jan; 18(1):25-32. PubMed ID: 16344616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?
    Cappelli S; Bellando-Randone S; Guiducci S; Matucci-Cerinic M
    Rheumatology (Oxford); 2014 Jun; 53(6):975-87. PubMed ID: 24185765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of systemic sclerosis.
    Manno R; Boin F
    Immunotherapy; 2010 Nov; 2(6):863-78. PubMed ID: 21091117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
    Volkmann ER; Tashkin DP
    Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the treatment of systemic sclerosis.
    Bournia VK; Vlachoyiannopoulos PG; Selmi C; Moutsopoulos HM; Gershwin ME
    Clin Rev Allergy Immunol; 2009 Jun; 36(2-3):176-200. PubMed ID: 19132559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and management of small vessel vasculitides].
    Pettersson T; Karjalainen A
    Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies.
    Schiavo AL; Puca RV; Ruocco V; Ruocco E
    Clin Dermatol; 2010; 28(3):337-43. PubMed ID: 20541689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].
    Rufino Hernández JM; Cabello Moya E; González-Posada JM; Hernández Marrero D; Pérez Tamajón L; Marrero Miranda D; García Rebollo S; Martín Urcuyo B; Rodríguez Hernández A; Franco Maside A; Barrios del Pino Y; Rodríguez Rodríguez R; Maceira Cruz B; Torres Ramírez A; Salido Ruiz E
    Nefrologia; 2010; 30(2):252-7. PubMed ID: 20098463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graves' disease associated with primary systemic sclerosis.
    Wimmersberger Y; Zuercher D
    Orbit; 2009; 28(4):262-3. PubMed ID: 19839886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seeking approval: present and future therapies for pemphigus vulgaris.
    Mao X; Payne AS
    Curr Opin Investig Drugs; 2008 May; 9(5):497-504. PubMed ID: 18465660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease in systemic sclerosis.
    Bussone G; Mouthon L
    Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Algorithms for Systemic Sclerosis According to Experts.
    Fernández-Codina A; Walker KM; Pope JE;
    Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Tervaert JW; Stegeman CA; Kallenberg CG
    Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):211-7. PubMed ID: 11224696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.